Pharma Distribution M&A Opportunity
Having unlocked the next case study of this Theme Vitrine , here is the deal:
Mongolia
“Mongolia’s land area is roughly equivalent to that of the countries of western and central Europe” and it is surrounded by other giants in the form of China, Russia and Kazakhstan. Yet it has only 3.3 million people and 4x the sheep heads.
Its main economic activity and driver is mining with a share of almost a quarter of the GDP. For example: “Oyu Tolgoi is one of the largest known copper and gold deposits in the world”It is largely an export-import-dependent nation with the bulk of its exports sold to China in the form of coal and copper, both having negative direct land & indirect health effects from excavation.By contrast, health and education have been focal to every government in Mongolia (all democratically elected since the 90s!), with the healthcare expenditure rising to over $500 per capita.Despite state-owned health facilities being a regular occurrence in Mongolia, the private sector has grown in importance. So for example, even the former state incumbent distributor MEIC (Mongol Em Impex Concern established in 1923) was privatized to Bishrelt Holding in 2006.
Mongolian pharma market is formed by:
40 local producers
Local production mainly consists of small producers producing old generics, traditional medicines & vitamins, with Monos and some foreign JVs being exceptions rather than a rule
120 wholesalers
Top 10 wholesale pharma distributors / importers take over 80% of the market: MEIC, Monos, Asiapharma, Ento, Europharma, Munkhiin Tun, Dakalpharma, Ombol, Monpha Trade, Tsahiur Tomor
1,300 retailers
250 outlets within state-owned hospitals, 250 pharmacies part of a chain/retail network such as Monos, and the rest independent outlets licensed by individual pharmacists
60 source-countries of imports
Russia, Germany, Slovenia, Hungary, India, Bulgaria, France, Austria, S.Korea, China… (most of the raw material comes from China and S.Korea)
An estimated 15-20% of pharma products are sold illegally in the country, a similar estimate to that of Kyrgyzstan pharma market.
Photo:BH
Mongolia’s pharmaceuticals sector has doubled over the last decade, from about $60mil to about $100mil, depending on the definition. This translates to +/-$30 per capita, still leaving a significant upside to catch up to comparable peers. So for example this in line where neighbouring Kazakhstan @ $32/cap was 12 years ago.
All in line with pharma consumption being very much related to increasing living standards, whereby health consciousness translates to a stronger demand for preventive medicine, food supplements and vitamins.
Currently, Mongolian drug consumption is still very much a developing world type, with the top five categories being antibiotics, digestives, cardiovascular, neurotropic & respiratory medicines.
There are seven government bodies or agencies involved in the pharma market regulation, which can be viewed as relatively lenient compared to some peer countries. The following functions and/or periodic (re)licensing / review / approval: licensing of manufacturing, licensing of importation, licensing of wholesale, licensing of retail, product assessment and registration, GMP Inspection, inspection of distribution channels, import control, quality control of products, control of medicines promotion& advertising, price control for the essential list, generic substitution, control of prescribing, technical elements (standards, norms, guidelines, procedures).
Monos is a family business started by brother and sister Luvsan in 1990, as a small pharma & cosmetics workshop producing skin treatment creams, powders and solutions for respiratory diseases using local herbal ingredients.
Being a pharmacologist by training, educated in the former USSR, the brother was an industry insider having worked for the Pharmaceuticals Institute and MEIC, a former state import & distribution monopoly.
It has diversified into other sectors over the last decade but with pharmaceuticals still at its heart. With 1,600 employees and 30 businesses, the group as a whole is a significant contributor to employment and state taxes.
Photo:BB
Monos operates a nationwide wholesale & distribution network, and a pharmacy chain (mainly in Ulaanbaatar and Central Mongolia). It also has a number of drug-, cosmetic- & health-foods-making facilities, which manufacture approx.100 types of medicines including 30 own brands. The retail chain has 90 pharmacy stores, a roughly equivalent amount to the incumbent competitor.
Mr. Luvsan / Monos won a number of state awards including for scientific research on kidneys and immune booster development. Given that the country relies on 80% of its drug consumption from imports, a rare event is that its own brand Nefromon is exported to Russia since 2014. Today the business has a pharma academy and medical research centres for bolstering innovation and future growth.
Production technology, WHO GMP-compliant and financed by the EBRD, allows for manufacturing of plain tablets, coated tablets, galen, capsules, powder, pills, cream, talcum powder, liquid, extract & syrup.
Monos’ pharmaceutical market share is probably at about a third of what is estimated to be just about a $100mil total pharma market, depending on the definition. Whereby being a straight-out leader in local production, which in total accounts for less than 20% of pharmaceutical demand in the country; a joint co-leader in wholesale with the sate MEIC; and a top player in the fragmented retail space.
Probably operating at a consolidated pharma EBITDA of 15-20%, where profitability from better to worse goes from own production to drug wholesale to retail outlets.
Given Mongolia’s landlocked status & relative isolation, its harsh winters with related seasonality, and high import dependence coupled with relative unfavourable supplier terms given the size of the production & overall significance in world markets- pharma business should have a longer asset conversion cycle than some comparable peer countries.
Managing working capital where a lot of cash is tied up, and in particular inventory turnover, is of great importance for its distribution units. At perceived volumes, modernised facilities and installed ERP, inventory days-on-hand should probably aim at (+/-): 100 days for the main warehouse, with logistics sub-points & city outlets at around 25 days, while areas outside Ulaanbaatar should be allowed up to 75 days.
The company should be well bankable (strong fixed asset base, reasonable net debt, predictable & growing cash flow, etc.), if it did not get too playful with the non-core businesses, and should be easily able to organically operate solely with the local financial institutions. It also does not look like that Monos has potential problems with succession, as it remains largely an extended family affair. On the other hand, it could have going public potential.!?
Theme Contribution
Madina Umarova
Experienced consultant with a demonstrated history of working in the industry. Skilled in commercial and nonprofit activity. Strong in business development, HR, marketing and administration.
Madina also is:
- Vice president, head of economic group (CIS), Coordinating Council of Russian compatriots in Croatia
- Founder of the Russian culture club in Croatia
- Teacher of Russian language and literature (& business comm)
And was:
- KPMG senior office administrator
- Professor at Law university
- Club administrator
- Cello instructor
Theme Related Tracker
- Another monkey virus could be poised for spillover to humanson October 4, 2022
An obscure family of viruses, already endemic in wild African primates and known to cause fatal Ebola-like symptoms in some monkeys, is “poised for spillover” to humans, according to new University of Colorado Boulder research published online Sept. 30 in the journal Cell.
- The Nobel Prize in Physiology or Medicine 2022on October 3, 2022
The Nobel Assembly at Karolinska Institutet has today decided to award the 2022 Nobel Prize in Physiology or Medicine to Svante Pääbo for his discoveries concerning the genomes of extinct hominins and human evolution.
- Non-opioid compounds squelch pain without sedationon September 30, 2022
A newly identified set of molecules alleviated pain in mice while avoiding the sedating affect that limits the use of opiates, according to a new study led by researchers at UC San Francisco. The molecules act on the same receptor as clonidine and dexmedetomidine - drugs commonly used in hospitals as sedatives - but are chemically unrelated to them and may not be addictive.
- Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19on September 29, 2022
AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID‑19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19.
- Breakthrough brings potential glioblastoma drug into focuson September 28, 2022
Glioblastoma, the most common cancerous brain tumor in adults, is an aggressive disease - patients survive an average of just 15 months once they are diagnosed. Despite more than two decades of research on the causes and treatments of glioblastoma, that prognosis has hardly improved.
- Machine learning creates opportunity for new personalized therapieson September 28, 2022
Researchers at the University of Michigan Rogel Cancer Center have developed a computational platform that can predict new and specific metabolic targets in ovarian cancer, suggesting opportunities to develop personalized therapies for patients that are informed by the genetic makeup of their tumors. The study appeared in Nature Metabolism.
- Similar medications cost more for humans compared to petson September 27, 2022
In a research letter published in JAMA Internal Medicine, University of Minnesota researchers compared the prices of 120 medications commonly used in humans and pets. The authors found the price of human medications was generally higher than the price of pet medications with the same ingredients at common human-equivalent doses.
- National CDC-funded study confirms that mRNA vaccines protect against serious COVID-19 during pregnancyon September 26, 2022
The first large, real-world study of the effectiveness of mRNA COVID-19 vaccines during pregnancy found these vaccines, especially two initial doses followed by a booster, are effective in protecting against serious disease in expectant mothers whether the shots are administered before or during pregnancy.
- 2nd Annual Next Generation Pharmaceutical Cleanrooms Conferenceon September 23, 2022
5 - 6 October 2022, London, United Kingdom. SAE Media Group are pleased to announce the 2nd Annual Next Generation Pharmaceutical Cleanroom Conference. An event that focuses on cleanroom technology in the pharmaceutical industry, the conference will serve to bridge that gap between the two areas while simultaneously providing a unique selling point.
- Pfizer to supply Global Fund up to 6 million PAXLOVID™ treatment courses for low-and-middle-income countrieson September 22, 2022
Pfizer Inc. (NYSE: PFE) announced today an agreement to supply up to six million treatment courses of its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) to Global Fund as part of its COVID-19 Response Mechanism (C19RM). The C19RM has been the primary channel for providing grant support to low- and middle-income countries to purchase COVID-19 tests, treatments, personal protective equipment and critical elements of health systems strengthening.
